KMT2A (Lysine Methyltransferase 2A)

A key epigenetic regulator in hematopoiesis and leukemia

Gene Information Card

Symbol KMT2A
Full Name Lysine Methyltransferase 2A
Gene Type Protein coding
Chromosomal Location 11q23.3
NCBI Gene ID 4297 ncbi.nlm.nih.gov/gene/4297
Ensembl ID ENSG00000118058
UniProt ID Q03164
OMIM ID 159555
HGNC ID 7132
Aliases MLL, ALL-1, CXXC7, HRX, HTRX1, MLL1, TRX1

Description

KMT2A (lysine methyltransferase 2A), also known as MLL, encodes a transcriptional coactivator that methylates histone H3 lysine 4 (H3K4). It is essential for normal hematopoiesis and embryonic development. Chromosomal rearrangements involving KMT2A are recurrent in acute leukemias, particularly in infant and therapy-related cases.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Acute lymphoblastic leukemia (ALL) KMT2A rearrangements (e.g., t(4;11)(q21;q23) producing KMT2A-AFF1 fusion) drive leukemogenesis by aberrant transcriptional activation ClinVar, COSMIC
Acute myeloid leukemia (AML) KMT2A partial tandem duplications (PTD) or fusions (e.g., KMT2A-MLLT3) alter H3K4 methylation and gene expression ClinVar, COSMIC
Wiedemann-Steiner syndrome Heterozygous loss-of-function mutations in KMT2A cause this autosomal dominant disorder with intellectual disability and hypertrichosis OMIM, ClinVar

Expression Profile

Tissue Expression
Tissue nTPM level
Bone marrow 12.5 Medium
Whole blood 8.3 Low
Brain 6.1 Low
Lymph node 15.2 Medium
Cell Line Expression
Cell Line nTPM Notes
K562 (leukemia) 18.4 High expression
HEK293 9.7 Moderate expression
HeLa 7.2 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
KMT2A-AFF1 fusion Chromosomal translocation Common in infant ALL Oncogenic fusion protein disrupts normal H3K4 methylation
KMT2A partial tandem duplication Intragenic duplication ~5-10% of AML Gain-of-function leading to HOX gene overexpression
p.Arg3762* Nonsense Rare Loss-of-function associated with Wiedemann-Steiner syndrome
Mutation functional classification

Loss of Function (LOF)

Nonsense or frameshift mutations in KMT2A reduce H3K4 methyltransferase activity, linked to Wiedemann-Steiner syndrome.

Gain of Function (GOF)

Partial tandem duplications (PTD) enhance HOX gene activation, contributing to AML.

Dominant Negative (DN)

Some KMT2A fusion proteins (e.g., KMT2A-AFF1) may act as dominant negatives by sequestering wild-type KMT2A complexes.

Gene Ontology (GO)

• Histone H3K4 methyltransferase activity • Chromatin binding
• Transcription coactivator activity • Regulation of transcription by RNA polymerase II
• Positive regulation of hematopoietic stem cell differentiation

Pathways

KMT2A-mediated H3K4 methylation
HOX gene activation in hematopoiesis
Mixed lineage leukemia (MLL) fusion protein signaling

Protein Summary

KMT2A (MLL) is a large multidomain protein (3969 amino acids) that catalyzes methylation of histone H3 lysine 4. It contains a SET domain responsible for methyltransferase activity, as well as AT-hooks, CXXC zinc finger, and PHD fingers that mediate DNA and chromatin binding. Proteolytic cleavage generates N-terminal (MLL-N) and C-terminal (MLL-C) fragments that associate to form a stable complex. Rearrangements of KMT2A are among the most common genetic alterations in acute leukemias.

Related Products

Product name Cat.No. Species Gene ID
KMT2A Knockout HEK293 Cell Line EDJ-KQ50442 Human 4297 Details Get a Quote
KMT2A Knockout HeLa Cell Line EDJ-KQ53877 Human 4297 Details Get a Quote
KMT2A Knockout A-549 Cell Line EDJ-KQ62368 Human 4297 Details Get a Quote
KMT2A Knockout HCT 116 Cell Line EDJ-KQ70837 Human 4297 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: